CA
BBNX

Clearstead Advisors’s Beta Bionics BBNX Stock Holding History

Clearstead Advisors’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-90
Closed -$1.31K – 3286
2025
Q2 		$1.31K Hold
90
– – ﹤0.01% 2398
2025
Q1 		$1.1K Buy
+90
New +$1.68K ﹤0.01% 1978

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Clearstead Advisors's BBNX Position: Q3 2025 in Review

Clearstead Advisors sold out of Beta Bionics (BBNX) in Q3 2025, closing a stake of 90 shares — an estimated $1.31K sold.

Clearstead Advisors first reported a position in BBNX in Q1 2025 and held it in 2 quarters. The position peaked at $1.31K in Q2 2025. 129 funds tracked by Wall St. Rank hold BBNX as of Q3 2025.

  • Clearstead Advisors reported no remaining Beta Bionics position as of Q3 2025 after selling out during the quarter.
  • Clearstead Advisors sold 90 Beta Bionics shares in Q3 2025, an estimated $1.31K.
  • Clearstead Advisors first reported a position in Beta Bionics in Q1 2025 and held it in 2 quarters.
  • Clearstead Advisors's Beta Bionics position peaked at $1.31K in Q2 2025.
  • 129 funds tracked by Wall St. Rank held Beta Bionics as of Q3 2025.

Based on Clearstead Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.